Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

M.K. van der Kooij, O.M. Dekkers, M.J.B. Aarts, F.W.P.J. van den Berkmortel, M.J. Boers-Sonderen, J.W.B. de Groot, G.A.P. Hospers, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, H.M. Westgeest, A.A.M. van der Veldt, G. Vreugdenhil, S. Wilgenhof, M.W.J.M. Wouters, J.B.A.G. Haanen, A.J.M. van den Eertwegh, E. Kapiteijn*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number4639
Number of pages13
JournalCancers
Volume13
Issue number18
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • advanced melanoma
  • immunotherapy
  • prospective nation-wide data
  • sex
  • targeted therapy
  • SURVIVAL
  • EUROPEAN ORGANIZATION
  • STAGE
  • POOLED ANALYSIS
  • BRAF
  • EXPRESSION
  • CLINICOPATHOLOGICAL FEATURES

Cite this